Agensys Company Profile

17:32 EST 13th December 2018 | BioPortfolio

Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validated a rich portfolio of novel, clinically relevant cancer targets to 14 different cancer types that have been carefully selected to enable development of new effective therapeutics with fewer and less severe side effects. All of Agensys' cancer targets must meet the following criteria: (1) a novel molecule and/or a novel utility in cancer; (2) expression in a significant percentage of patients' specimens; (3) limited expression in normal vital tissues; and (4) structural and functional features suitable for therapeutic intervention. The Company is generating fully human antibodies to multiple targets from its portfolio, including those directed to prostate, kidney, bladder, colon, lung, ovary and pancreatic cancers. The Company's portfolio also contains multiple validated targets for small molecule and vaccine products that it intends to develop through partnerships with pharmaceutical and biotechnology companies.


1545 17th Street
Santa Monica
United States of America


Phone: (310) 820-8029
Fax: (310) 820-8489

News Articles [2 Associated News Articles listed on BioPortfolio]

Former Agensys Exec David Stover Joins i2 Pharmaceuticals as CEO

David Stover has been appointed CEO of Boulder, CO-based cancer drug developer i2 Pharmaceuticals. Stover was most recently an executive at Agensys, a Santa Monica, CA, oncology subsidiary of Japanese...

Global Cancer Tubulin Inhibitors Market Status and Outlook 20182025 [Report Updated: 18082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynam...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validat...

Seattle Genetics, Inc.

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and ...

More Information about "Agensys" on BioPortfolio

We have published hundreds of Agensys news stories on BioPortfolio along with dozens of Agensys Clinical Trials and PubMed Articles about Agensys for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Agensys Companies in our database. You can also find out about relevant Agensys Drugs and Medications on this site too.

Quick Search


Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record